Greenwich Lifesciences Inc (GLSI NASDAQ) stock market data APIs
$9.4171
0.23(2.4%)
as of June 9, 2025
Try our APIs with
free plan!
Greenwich Lifesciences Inc Financial Data Overview
Prev. Close
9.4171
Open
9.6489
High
9.6489
Low
9.4626
52 wk Range
8.06-18.7499
Market Cap
126 M
Shares Outstanding
13 368 K
EPS
-0.25
Beta
3.25
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Greenwich Lifesciences Inc data using free add-ons & libraries
Get Greenwich Lifesciences Inc Fundamental Data
{
"General": {
"Code": "GLSI",
"Type": "Common Stock",
"Name": "Greenwich Lifesciences\u00a0Inc",
"Exchange": "NASDAQ",
"CurrencyCode": "USD",
"CurrencyName": "US Dollar",
"CurrencySymbol": "$",
"CountryName": "USA",
"CountryISO": "US",
"OpenFigi": "BBG00V6PT8C7",
"ISIN": null,
"CUSIP": null,
"CIK": "0001799788",
"EmployerIdNumber": null,
"FiscalYearEnd": "December",
"IPODate": "2020-09-25",
"InternationalDomestic": null,
"Sector": "Healthcare",
"Industry": "Biotechnology",
"HomeCategory": null,
"IsDelisted": false,
"Description": "Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2\/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in p..."
}
}Greenwich Lifesciences Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -16 753 336
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-19
- EPS/Forecast: -0.24
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Greenwich Lifesciences Inc News
New
Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial
STAFFORD, Texas, April 02, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, F...
Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026
STAFFORD, Texas, March 27, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, F...
Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01
STAFFORD, Texas, March 17, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, F...
Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01
STAFFORD, Texas, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FL...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
